David Day and a lifetime of missed moments

David Day and a lifetime of missed moments

8 June 2018

“I couldn’t eat. Barely slept. I was the one to tell Dave it was all over. All Dave said was ‘my poor, poor babies’.”  Jenny, David’s wife.

When David lost his life last year, he was 33, with three daughters under six.

David Day was one of the 20% of people with advanced melanoma have primary resistance to new drugs with ‘super progression' and we need to find out why. 

The greatest challenge our clinicians currently face in treating melanoma is ‘super progression’.

Amid all our success stories, there is still a group of people with advanced melanoma for whom absolutely nothing works. About 20% of patients our medical oncologists see with advanced melanoma fall into this category.

Super progressors do not respond to existing treatments. Within a few short months, their disease progresses aggressively and relentlessly and we cannot save them.

David Day, was one such patient —a lovely young father with a wonderful family — who died last year.

The most agonising thing about patients like David is that at present, we just don’t know why they super progress.

Dr Inês Silva was part of the clinical team which treated David Day. She was studying at MIA as a Medical Oncology Fellow from Portugal. David had such a profound impact on Inês, that on completion of her Fellowship, she decided to stay on at MIA as a Research Scientist in an all-out attempt to find answers for super progressors.

Inês and the MIA research team collected blood and melanoma tissue samples from David during his treatment. They also collected similar samples from other advanced melanoma patients who have not responded to immunotherapy.

By studying the genomic profile and protein expression in each of these patients’ tumours, Ines and the MIA research team hope to understand why each drug failed to work, paving the way for new, and potentially life-saving therapies.

While there is some existing grant funding to cover her salary, a dedicated Research Scientist like Inês can’t do it alone.

We are relying on you and on the support of our donor community to collectively fund this research project including research assistants’ salaries, PhD student scholarship top-ups, equipment, and state-of-the-art research technologies such as DNA, RNA and cell sequencing. All are key to understanding and solving primary resistance and super progression.

David was a sweet, humble family man. He was a high-achiever, had forged an exceptional career as a computer engineer for Google and made a loving, happy life raising his three daughters Charlotte, 7, Emma, 5, and Annie, now 1, with his wife Jenny, his childhood sweetheart since Year 9.

Just before Christmas 2016, with Jenny heavily pregnant with little Annie, Dave found a lump under his left arm. He had Stage III melanoma. Half way through his treatment, David found another lump under his arm and a new tumour was discovered on his left hip. His melanoma had progressed to Stage IV.

In March 2017, David and Jenny were referred to Melanoma Institute Australia. He started on a clinical trial and at first, his scans looked promising.

After starting treatment, another painful melanoma appeared on David’s wrist. In the next three months, tumours sprang up in his spleen, lungs, pancreas, bones, under his skin —  with up to 30 more in his liver. Even though immune cells were present, David was super progressing.

As the months passed, David suffered extreme pain, liver damage, rapid weight loss, blurred vision and internal bleeding. The clinical team switched to chemotherapy as a last resort and Annie’s christening was pushed forward.

On 25 August 2017, Jenny had the worst imaginable task of explaining to her soul mate that nothing more could be done for him.

“I was the one to tell him it was over. All he could say was “My poor, poor babies”. My heart ached. I had lost 15kg over the past five months from the stress of the whole situation. My milk dried up and I couldn’t feed Annie. It ate away at me while I put on a brave face for Dave and the kids,” says Jenny.

Jenny has very generously shared her painful story in the hope that it will help raise funds to crack the riddle of super progression. 

Please give today to save someone you know from the ravages of melanoma in the future, and give them what David didn’t have- the opportunity to enjoy a lifetime of special moments with their loved ones.

Donate now

 

MIA contributes to major research breakthrough which pioneers a new way of treating cancer
01 Jun 2015

MIA contributes to major research breakthrough which pioneers a new way of treating cancer

The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.

Q&A with our Clinical Research Fellow
26 May 2015

Q&A with our Clinical Research Fellow

We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam

International Clinical Trials Day marked
20 May 2015

International Clinical Trials Day marked

Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research. 

5 minutes with Practice Manager Sherrie D'Souza
15 May 2015

5 minutes with Practice Manager Sherrie D'Souza

We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role. 

Associate Professor Georgina Long has won the InStyle Women In Style Award
14 May 2015

Associate Professor Georgina Long has won the InStyle Women In Style Award

Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category. 

The Federal Government's 2015-16 Budget announcements benefit research
14 May 2015

The Federal Government's 2015-16 Budget announcements benefit research

The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding. 

Professor Thompson made an honorary member of the American Surgical Association
01 May 2015

Professor Thompson made an honorary member of the American Surgical Association

The Association's members include prominent surgeons from around the world. 

MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
20 Apr 2015

MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients

This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers. 

Anti-PD1 immunotherapy pembrolizumab (KEYTRUDA®) has been registered by the TGA
20 Apr 2015

Anti-PD1 immunotherapy pembrolizumab (KEYTRUDA® ) has been registered by the TGA

Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.

MIA's Autumn Newsletter
12 Apr 2015

MIA's Autumn Newsletter

Our Autumn newsletter has been published and we have our digital version online now. 

Professor John Thompson appointed to Australian Academy of Health and Medical Sciences
31 Mar 2015

Professor John Thompson appointed to Australian Academy of Health and Medical Sciences

Professor John Thompson, Executive Director at Melanoma Institute Australia, was one of 116 fellows appointed to the new Australian Academy of Health and Medical Sciences at a ceremony in Canberra on the 25th March.

Melanoma Institute part of $14m melanoma project grant
25 Mar 2015

Melanoma Institute part of $14m melanoma project grant

Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.

Melanoma March Bibs
19 Mar 2015

Melanoma March Bibs

If you would like to download a bib for your Melanoma March, we have a selection for you to choose from, print and bring along with you on the day. 

Manly Melanoma March
17 Mar 2015

Manly Melanoma March

Manly Melanoma March has changed to a new location. 

Q&A with Melanoma March Fundraisers
10 Mar 2015

Q&A with Melanoma March Fundraisers

We did a short Q&A with two sisters who are raising funds for Melanoma March after sadly losing their mother in 2009. This is their second march and they have shared with us their fundraising tips. 

Research Director Graham Mann explains where Melanoma March funds are going
10 Mar 2015

Research Director Graham Mann explains where Melanoma March funds are going

We want to share with you what your valuable Melanoma March donation and fundraising goes towards and our Research Director, Graham Mann explains the national research project the funds will be going towards.

First patient recruited to the EAGLE FM Trial
09 Mar 2015

First patient recruited to the EAGLE FM Trial

Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma (EAGLE FM) clinical trial has recruited its first patient.  

Online Comments to the Pharmaceutical Benefits Advisory Committee
09 Feb 2015

Online Comments to the Pharmaceutical Benefits Advisory Committee

You are invited to provide comments for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC will consider the registration of the anti-PD1 drug, Keytruda (pembrolizumab) at the next meeting in March.

A man of commitment
06 Feb 2015

A man of commitment

Melanoma patient Joel Allsop was congratulated today on completing his participation in the international surgical clinical trial, known as MSLT-II. He was the first person in the world to complete the 10 years of follow-up for this trial.